Reply: Biological Plausibility Behind the Benefits of Intravenous Metoprolol in Severe COVID-19

J Am Coll Cardiol. 2022 Jan 4;79(1):e13-e14. doi: 10.1016/j.jacc.2021.10.030.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Administration, Intravenous
  • Adrenergic beta-1 Receptor Antagonists
  • COVID-19*
  • Humans
  • Metoprolol*
  • SARS-CoV-2

Substances

  • Adrenergic beta-1 Receptor Antagonists
  • Metoprolol